Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus /von 2019-04-29 / Int. J. Cancer 2019 10;145(7):1958-1969The Effect of Vitamin C (Ascorbic Acid) in the Treatment of Patients with Cancer: A Systematic Review
/in International Publications, Micronutrients /von 2019-04-28 / Nutrients 2019 Apr;11(5)A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2019-04-27 / Trials 2019 Apr;20(1):242Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia
/in Acute Leukemia, Dendritic Cells, International Publications /von 2019-04-27 / J Clin Med 2019 Apr;8(5)Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals
/in Dendritic Cells, HIV/AIDS, International Publications /von 2019-04-24 / Front Immunol 2019;10:874Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis
/in Cervical Cancer, International Publications, Newcastle Disease Virus /von 2019-04-23 / Saudi J Biol Sci 2020 Jan;27(1):47-52Radiofrequency deep hyperthermia combined with chemotherapy in the treatment of advanced non-small cell lung cancer
/in Hyperthermia, International Publications, NSCLC /von 2019-04-20 / Chin. Med. J. 2019 Apr;132(8):922-927A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials
/in Dendritic Cells, Glioblastoma, International Publications /von 2019-04-15 / Cancers (Basel) 2019 Apr;11(4)Curcumin: New Insights into an Ancient Ingredient against Cancer
/in Curcuma, International Publications /von 2019-04-12 / Int J Mol Sci 2019 Apr;20(8)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de